Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
43 hedge funds and large institutions have $14.7M invested in Zynerba Pharmaceuticals, Inc in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 14 closing their positions.
747% more capital invested
Capital invested by funds: $1.74M → $14.7M (+$13M)
67% more call options, than puts
Call options by funds: $45K | Put options by funds: $27K
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
5% more funds holding
Funds holding: 41 → 43 (+2)
73% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$4.28M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$1.99M |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$541K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$416K |
| 5 |
DAM
Deltec Asset Management
New York
|
+$415K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$711K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$305K |
| 3 |
BlackRock
New York
|
-$241K |
| 4 |
Renaissance Technologies
New York
|
-$73.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$64.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of New York Mellon
New York
| – | -$8.58K | -26,311 | Closed |
|
|
RJFSA
52
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$4.53K | -13,900 | Closed |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$10.7K | -12,295 | -98% |
|
54
Group One Trading
Chicago,
Illinois
| – | -$3.98K | -4,559 | Closed |
|
|
TWC
55
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$1.73K | -4,145 | Closed |
|
56
Fidelity Investments
Boston,
Massachusetts
| – | -$8 | -25 | Closed |
|
|
IA
57
IFP Advisors
Tampa,
Florida
| – | -$7 | -23 | Closed |
|
ZYNE Hedge Fund Activity: Q3 2023 in Review
43 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2023, worth a combined $14.7M — up 747% from $1.74M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ZYNE positions and 14 closed out — a net gain of 3 holders — while 3 added to existing stakes and 11 trimmed.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $4.28M. The largest seller was Vanguard Group, exiting entirely with an estimated $711K sold.
- 43 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2023, up from 41 in Q2 2023.
- Funds reported $14.7M of Zynerba Pharmaceuticals, Inc stock for Q3 2023, up 747% quarter-over-quarter.
- 17 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2023 and 14 closed out, a net change of +3 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2023 was Beryl Capital Management, an estimated $4.28M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2023 was Vanguard Group, an estimated $711K sold.
Based on aggregated 13F filings for Q3 2023.